Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort.
Parkinson's disease, gastrointestinal symptoms, anti‐parkinsonian medications, non‐motor symptoms
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
13
09
2020
revised:
19
11
2020
accepted:
02
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
While constipation is a well-known non-motor symptom which may precede the onset of the classical motor symptoms of PD, there have been few comprehensive studies of gastrointestinal (GI) symptoms in people with PD (PwP). To investigate the spectrum of GI symptoms in an Australian PwP cohort and their relationship to use of anti-parkinsonian medications dietary habits and smoking. The prevalence and severity of GI symptoms were compared in a group of 163 PwP and 113 healthy control subjects using the Gastrointestinal Symptom Rating Scale (GSRS). Corrected linear regression models were used to determine differences between PwP and controls, and to investigate the influence of different classes of anti-Parkinsonian medications. PwP reported a greater frequency of constipation and GI-associated illnesses when compared to healthy controls. Total GSRS scores ( This study illustrates the frequency and array of GI symptoms in a large PD cohort. The findings indicate that anti-parkinsonian medications play an important role in the presentation and development of GI symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
While constipation is a well-known non-motor symptom which may precede the onset of the classical motor symptoms of PD, there have been few comprehensive studies of gastrointestinal (GI) symptoms in people with PD (PwP).
OBJECTIVES
OBJECTIVE
To investigate the spectrum of GI symptoms in an Australian PwP cohort and their relationship to use of anti-parkinsonian medications dietary habits and smoking.
METHODS
METHODS
The prevalence and severity of GI symptoms were compared in a group of 163 PwP and 113 healthy control subjects using the Gastrointestinal Symptom Rating Scale (GSRS). Corrected linear regression models were used to determine differences between PwP and controls, and to investigate the influence of different classes of anti-Parkinsonian medications.
RESULTS
RESULTS
PwP reported a greater frequency of constipation and GI-associated illnesses when compared to healthy controls. Total GSRS scores (
CONCLUSIONS
CONCLUSIONS
This study illustrates the frequency and array of GI symptoms in a large PD cohort. The findings indicate that anti-parkinsonian medications play an important role in the presentation and development of GI symptoms.
Identifiants
pubmed: 33553495
doi: 10.1002/mdc3.13134
pii: MDC313134
pmc: PMC7853192
doi:
Types de publication
Journal Article
Langues
eng
Pagination
245-253Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Déclaration de conflit d'intérêts
This study was funded by Parkinson's WA Zrinski Research Grant 2019, Perron Institute of Neurological and Translational Science, and The University of Notre Dame Australia. The authors declare that there are no conflicts of interest relevant to this work.
Références
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Mov Disord. 2014 Apr;7(1):7-12
pubmed: 24926404
J Parkinsons Dis. 2017;7(2):359-367
pubmed: 28157109
United European Gastroenterol J. 2020 Apr;8(3):284-292
pubmed: 32213021
Scand J Gastroenterol Suppl. 1996;221:8-13
pubmed: 9110389
Mov Disord. 2006 Aug;21(8):1270-3
pubmed: 16700046
J Neurol Sci. 2012 Aug 15;319(1-2):86-8
pubmed: 22632782
Arq Gastroenterol. 2016 Jul-Sep;53(3):146-51
pubmed: 27438418
Mov Disord. 2013 Aug;28(9):1241-9
pubmed: 23712625
Mov Disord. 2007 Oct 15;22(13):1901-11
pubmed: 17674410
Mov Disord. 2015 Mar;30(3):350-8
pubmed: 25476529
Drugs. 2000 Jun;59(6):1233-50
pubmed: 10882160
NPJ Parkinsons Dis. 2019 Jun 10;5:10
pubmed: 31231674
J Neurol. 2013 May;260(5):1332-8
pubmed: 23263478
Med J Aust. 2010 Feb 1;192(3):144-9
pubmed: 20121682
Health Qual Life Outcomes. 2008 Jan 31;6:12
pubmed: 18237386
Mov Disord. 2010 Apr 30;25(6):704-9
pubmed: 20437539
Parkinsonism Relat Disord. 2018 May;50:23-28
pubmed: 29459115
Qual Life Res. 1998 Jan;7(1):75-83
pubmed: 9481153
Parkinsons Dis. 2019 Aug 20;2019:3897315
pubmed: 31531219
Mov Disord Clin Pract. 2018 Oct 09;5(5):461-470
pubmed: 30515435
Mov Disord. 1991;6(2):151-6
pubmed: 2057006
J Cell Physiol. 2017 Sep;232(9):2359-2372
pubmed: 27512962
Mov Disord. 1993;8(1):83-6
pubmed: 8093549
J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):710-6
pubmed: 26345189
Parkinsons Dis. 2019 Jun 19;2019:7935820
pubmed: 31321021
Mov Disord Clin Pract. 2019 Oct 23;6(8):639-651
pubmed: 31745471
Lancet Neurol. 2009 May;8(5):464-74
pubmed: 19375664
Mov Disord. 2017 May;32(5):739-749
pubmed: 28195358
Mov Disord. 2015 Sep;30(10):1351-60
pubmed: 26179554
Mov Disord. 2001 Nov;16(6):1041-7
pubmed: 11748735
J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1503-7
pubmed: 3221217
Br J Hosp Med (Lond). 2014 Jan;75(1):18-24
pubmed: 24401966
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Parkinsons Dis. 2016;2016:6762528
pubmed: 28050310
Clin Drug Investig. 2004;24(4):205-15
pubmed: 17516705
Parkinsonism Relat Disord. 2002 Mar;8(4):277-84
pubmed: 12039423
Parkinsonism Relat Disord. 2014 Dec;20(12):1371-5
pubmed: 25293395
Sci China Life Sci. 2017 Nov;60(11):1223-1233
pubmed: 28536926
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944
Mov Disord. 2014 Jan;29(1):23-32
pubmed: 24151126
Qual Life Res. 2006 Sep;15(7):1223-32
pubmed: 16972162
Mov Disord. 2011 Apr;26(5):889-92
pubmed: 21520278
Mov Disord. 2010 Nov 15;25(15):2493-500
pubmed: 20922807
Front Neurosci. 2019 Aug 07;13:839
pubmed: 31440136
Australas Ann Med. 1965 Feb;14:13-22
pubmed: 14271784
World J Gastroenterol. 2016 Oct 14;22(38):8540-8548
pubmed: 27784966
Dig Dis Sci. 1988 Feb;33(2):129-34
pubmed: 3123181
Toxicol Sci. 2013 Jan;131(1):9-12
pubmed: 22923489
Nutr J. 2016 Mar 15;15:26
pubmed: 26979712
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639
Clin Interv Aging. 2010 Sep 07;5:229-38
pubmed: 20852670
J Neurol. 2020 May;267(5):1377-1388
pubmed: 31989280
J Parkinsons Dis. 2017;7(3):471-479
pubmed: 28759975
Mov Disord. 2018 Jan;33(1):88-98
pubmed: 28843021
Mov Disord. 2020 Jul;35(7):1208-1217
pubmed: 32357258
Mov Disord Clin Pract. 2019 Feb 05;6(3):227-234
pubmed: 30949554
J Neurol. 2004 Oct;251 Suppl 7:vII18-23
pubmed: 15505750
Scand J Gastroenterol. 1995 Nov;30(11):1046-52
pubmed: 8578162
Dig Liver Dis. 2019 Jan;51(1):38-42
pubmed: 30309751
Curr Opin Rheumatol. 2013 Nov;25(6):700-6
pubmed: 24047604
J Clin Neurol. 2016 Apr;12(2):147-50
pubmed: 26932258
Mov Disord. 2020 Jan;35(1):116-133
pubmed: 31571279